NASDAQ · CDT
Healthcare · Biotechnology
$0.13
Down-$0.00 (-0.08%)
Updated Oct 24, 2026, 5:37 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CDT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
CDT closed at $0.13 after 21 trading sessions, down 93.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $0.1316 | $0.1737 | $0.1248 | $0.13 | 5.98M |
| Oct 22, 2026 | $0.1409 | $0.1442 | $0.1282 | $0.1301 | 2.18M |
| Oct 21, 2026 | $0.1601 | $0.161 | $0.1381 | $0.1447 | 1.72M |
| Oct 20, 2026 | $0.1741 | $0.1776 | $0.1451 | $0.159 | 1.92M |
| Oct 19, 2026 | $0.1987 | $0.2086 | $0.1718 | $0.186 | 1.35M |
| Oct 16, 2026 | $0.1998 | $0.2423 | $0.192 | $0.2351 | 11.87M |
| Oct 15, 2026 | $0.1972 | $0.2167 | $0.1813 | $0.209 | 2.21M |
| Oct 14, 2026 | $0.2428 | $0.2519 | $0.195 | $0.24 | 22.35M |
| Oct 13, 2026 | $0.5913 | $0.6108 | $0.4146 | $0.45 | 966.4K |
| Oct 12, 2026 | $0.7023 | $0.7127 | $0.6311 | $0.66 | 373.03K |
| Oct 9, 2026 | $0.79 | $0.7966 | $0.6999 | $0.718 | 471.68K |
| Oct 8, 2026 | $0.8211 | $0.8509 | $0.796 | $0.80 | 264.69K |
| Oct 7, 2026 | $0.8987 | $0.8987 | $0.804 | $0.836 | 491.62K |
| Oct 6, 2026 | $0.90 | $0.94 | $0.851 | $0.9301 | 918.3K |
| Oct 5, 2026 | $0.9725 | $0.9725 | $0.8502 | $0.9177 | 352.78K |
| Oct 2, 2026 | $1.28 | $1.28 | $0.95 | $0.99 | 1.03M |
| Oct 1, 2026 | $1.34 | $1.3706 | $1.22 | $1.25 | 268.87K |
| Sep 30, 2026 | $1.45 | $1.5555 | $1.34 | $1.36 | 334.39K |
| Sep 29, 2026 | $1.87 | $1.8841 | $1.44 | $1.45 | 599.77K |
| Sep 28, 2026 | $1.875 | $1.93 | $1.71 | $1.90 | 1.22M |
| Sep 25, 2026 | $2.21 | $2.2175 | $1.965 | $2.00 | 1.07M |
The latest Smart Investors Daily articles mentioning CDT.
Company
Market Activity
Research & News
CDT research
Company profile and research snapshot.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Visit company websiteConsensus and target data currently published for this company.
Generated Oct 24, 2026, 3:08 PM
CDT Equity Inc. is experiencing minimal price movement, down just $0.00 (0.08%) in today's session as the broader healthcare sector shows mixed after-market activity. The stock appears caught in the typical Wednesday afternoon trading pattern alongside other healthcare equities, with no major company-specific catalysts driving significant directional momentum.
Bottom line: CDT Equity Inc. remains in a holding pattern with minimal price movement, reflecting a lack of near-term catalysts while remaining part of a broader healthcare sector trading day. Investors should monitor for upcoming earnings releases, analyst upgrades, or strategic developments that could break the current equilibrium, while remaining mindful of headwinds affecting the broader healthcare industry.
Benzinga · Oct 21, 2026
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Benzinga · Oct 20, 2026
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
Benzinga · Oct 19, 2026
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock
Benzinga · Oct 16, 2026
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stock
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CDT.
